Kairos Pharma, Ltd. (KAPA)
| Market Cap | 18.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.74M |
| Shares Out | 12.84M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,874 |
| Open | 1.450 |
| Previous Close | 1.470 |
| Day's Range | 1.410 - 1.534 |
| 52-Week Range | 1.220 - 4.000 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 9.00 (+516.44%) |
| Earnings Date | Nov 14, 2024 |
About KAPA
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-ĸβ pathway, a can... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for KAPA stock is "Strong Buy" and the 12-month stock price forecast is $9.0.
News
Kairos Pharma to Present at the LD Micro Main Event XVII
LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, wil...
Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, wil...
Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Serv...
U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost
Two small IPOs and two SPACs debuted this past week - Global Engine, Kairos Pharma, YHN Acquisition I, and Cayson Acquisition, respectively. Seven IPOs and three SPACs submitted initial filings. Eight...
Kairos Pharma Closing of $6.2 Million Initial Public Offering
LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics ...
Kairos Pharma Prices $6.2 Million Initial Public Offering
Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA” Company anticipates commencement of trading on the NYSE American effective Septemb...
Kairos Pharma to sell 1.55 million shares in IPO at $4 each
Kairos Pharma plans to sell about 1.55 million shares in its initial public offering at $4 per share.
Kairos Pharma Files For U.S. IPO
Kairos Pharma, Ltd. has filed for an IPO to raise an undisclosed amount of funds to advance its pipeline of cancer treatments. The company's lead candidate, ENV-105, is currently in Phase 2 clinical t...
Kairos Pharma IPO Registration Document (S-1)
Kairos Pharma has filed to go public with an IPO on the NASDAQ.